Tazobactum%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520piperacillin

# Piperacillin-tazobactam ## Overview Piperacillin-tazobactam is a combination antibiotic consisting of piperacillin, a broad-spectrum penicillin antibiotic, and tazobactam, a beta-lactamase inhibitor. Tazobactam protects piperacillin from degradation by many beta-lactamase enzymes, extending its spectrum of activity against beta-lactamase-producing bacteria. ## Primary Indications * Complicated intra-abdominal infections * Complicated skin and skin structure infections * Community-acquired pneumonia * Nosocomial pneumonia * Nosocomial intra-abdominal infections * Febrile neutropenia (empiric treatment) ## Adult Dosing Standard dosing is typically 3.375 grams (3g piperacillin/0.375g tazobactam) or 4.5 grams (4g piperacillin/0.5g tazobactam) intravenously every 6 or 8 hours. * **Complicated intra-abdominal infections, complicated skin and skin structure infections, community-acquired pneumonia, nosocomial pneumonia:** * 3.375 g IV every 6 hours OR 4.5 g IV every 6 or 8 hours. * Duration varies based on infection severity and clinical response, typically 7-14 days for complicated intra-abdominal infections. * **Febrile neutropenia:** * 4.5 g IV every 6 hours. * Duration depends on resolution of neutropenia and fever. Higher doses or extended infusions may be used in severe infections or for organisms with lower susceptibility. Specific dosing depends on local institutional protocols. ## Pediatric Dosing Dosing is based on piperacillin component. * **Children 2 months of age and older:** * **Complicated intra-abdominal infections:** 100 mg piperacillin/12.5 mg tazobactam per kg per dose IV every 8 hours. * **Nosocomial pneumonia:** 100 mg piperacillin/12.5 mg tazobactam per kg per dose IV every 8 hours. * **Febrile neutropenia:** 100 mg piperacillin/12.5 mg tazobactam per kg per dose IV every 6 hours. * **Maximum dose:** Not to exceed 3.375 g per dose (3g piperacillin/0.375g tazobactam). * **Neonates and infants younger than 2 months:** Dosing is not well-established. Use with caution and consider specific pharmacokinetic data if necessary. ## Dose Adjustments * **Renal Impairment (CrCl < 40 mL/min):** * **CrCl 20-40 mL/min:** 2.25 g IV every 6 hours or 3.375 g IV every 8 hours. * **CrCl < 20 mL/min:** 2.25 g IV every 8 hours or 3.375 g IV every 12 hours. * **Hemodialysis:** Give usual dose and an additional 0.75 g dose after each dialysis session. * **Hepatic Impairment:** No dose adjustment generally required. ## Contraindications * Hypersensitivity to piperacillin, tazobactam, other penicillins, or any component of the formulation. * History of cholestatic jaundice or hepatic dysfunction associated with piperacillin-tazobactam use. ## Adverse Effects * **Common:** Diarrhea, nausea, vomiting, rash, headache, insomnia, constipation, abdominal pain, fever, eosinophilia, elevated liver enzymes (AST, ALT). * **Serious:** *Clostridioides difficile*-associated diarrhea, severe hypersensitivity reactions (anaphylaxis), Stevens-Johnson syndrome, toxic epidermal necrolysis, seizures (especially with high doses or renal impairment), neutropenia, thrombocytopenia, prolonged bleeding time. ## Key Drug Interactions * **Probenecid:** May increase and prolong piperacillin-tazobactam serum concentrations. * **Neuromuscular blocking agents (e.g., vecuronium):** Piperacillin may prolong the neuromuscular blockade. * **Warfarin:** May decrease the effect of warfarin. Monitor INR closely. * **Methotrexate:** Penicillins may decrease the clearance of methotrexate. Monitor methotrexate levels. ## Monitoring * Renal function (creatinine, BUN) for dose adjustment. * Liver function tests (AST, ALT) periodically. * Complete blood count (CBC) to monitor for hematologic changes (neutropenia, thrombocytopenia). * Signs and symptoms of infection for clinical response. * Signs and symptoms of hypersensitivity reactions. * Stool for *C. difficile* if diarrhea occurs. ## Clinical Pearls * Piperacillin-tazobactam is a bactericidal agent. * The combination provides coverage against many gram-positive, gram-negative, and anaerobic bacteria, including many beta-lactamase producers. * It is a common choice for empiric therapy in serious infections, particularly in hospital-acquired settings. * Extended infusion (e.g., over 4 hours) may optimize outcomes in critically ill patients by maintaining drug concentrations above the minimum inhibitory concentration (MIC). * Reconstituted solutions should be used within specified timeframes due to potential degradation. *** **Disclaimer:** This information is intended for healthcare professionals and is not a substitute for clinical judgment. Always refer to the most current prescribing information and institutional guidelines before administering any medication.